STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism
STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.
Phase III
HER2+ breast cancer
Status
Active
Sponsor
Roche
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market.
Recommended action
Humanexa recommends Investigate: The recommended action to investigate is based on the potential for STARD10 to serve as a novel therapeutic target, which could lead to advancements in treatment options for HER2+ breast cancer.
Analysis
Monitor developments in therapies targeting lipid metabolism in HER2+ breast cancer and any clinical trials involving STARD10.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.